Literature DB >> 14576057

Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion.

Nasreen S Haque1, John T Fallon, Jiang Jin Pan, Mark B Taubman, Peter C Harpel.   

Abstract

The response of the arterial vascular wall to injury is characterized by vascular smooth muscle cell (VSMC) migration, a process requiring metalloproteinase production. This migration is induced by cytokines, however the agonists involved are not fully defined. The CC chemokine receptor 8 (CCR8) is expressed on monocytes and T lymphocytes and is the sole receptor for the human CC chemokine 1 (CCL1, I-309) and for the viral chemokine, vCCL1 (viral macrophage inflammatory protein 1 [vMIP-1]). We have reported that CCR8 is expressed on human umbilical vein endothelial cells (HUVECs) and mediates chemotaxis induced by CCL1. The conditioned medium from incubation mixtures of lipoprotein(a) (Lp(a)) and HUVECs (LCM) contained CCL1 and stimulated both monocyte and HUVEC chemotaxis, providing novel mechanisms for the atherogenicity of Lp(a). We now report that CCL1, vCCL1, and LCM stimulate chemotaxis of human VSMCs that is blocked by murine monoclonal antibody against CCR8 and by the G-protein inhibitor pertussis toxin. The effect of anti-CCR8 was specific, as this antibody failed to effect the chemotaxis of VSMCs in response to CCL3 or by platelet-derived growth factor BB (PDGF-BB). VSMCs contained CCR8 mRNA and CCR8 antigen coprecipitated with VSMC membranes. Antibodies against metalloproteinase-2 (MMP-2) inhibited the CCL1-induced chemotaxis of VSMCs, whereas anti-MMP-9 was less effective. CCL1 induced VSMC pro-MMP-2 mRNA and protein secretion. Poxvirus MC148 inhibited the increase in MMP-2 induced by CCL1, documenting that CCR8 was the receptor responsible. In mouse femoral arteries, CCR8 and TCA3 antigen colocalized with VSMCs and were up-regulated after injury. The induction of CCR8 and CCL1/TCA3 under conditions associated with VSMC proliferation and migration raises the possibility that CCR8 may play an important role in vessel wall pathology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576057     DOI: 10.1182/blood-2002-05-1480

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Toxin-induced RhoA activity mediates CCL1-triggered signal transducers and activators of transcription protein signaling.

Authors:  Simone Reipschläger; Katharina Kubatzky; Sanaz Taromi; Meike Burger; Joachim Orth; Klaus Aktories; Gudula Schmidt
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

2.  Human herpesvirus 8-encoded cytokines.

Authors:  John Nicholas
Journal:  Future Virol       Date:  2010-03       Impact factor: 1.831

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 5.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 6.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

7.  Treatment of Chronic Lower Extremity Ulcers with A New Er:Yag Laser Technology.

Authors:  J M Alcolea; E Hernández; P A Martínez-Carpio; M Vélez; V Khomchenko; A Sola; M A Trelles
Journal:  Laser Ther       Date:  2017-09-30

8.  CCR8 signaling influences Toll-like receptor 4 responses in human macrophages in inflammatory diseases.

Authors:  Martina Kvist Reimer; Charlotte Brange; Alexander Rosendahl
Journal:  Clin Vaccine Immunol       Date:  2011-10-05

9.  CC chemokine receptor-1 activates intimal smooth muscle-like cells in graft arterial disease.

Authors:  Koichi Shimizu; Manabu Minami; Rica Shubiki; Marco Lopez-Ilasaca; Lindsey MacFarlane; Yukiko Asami; Yuxin Li; Richard N Mitchell; Peter Libby
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

10.  Novel interactions between NFATc1 (Nuclear Factor of Activated T cells c1) and STAT-3 (Signal Transducer and Activator of Transcription-3) mediate G protein-coupled receptor agonist, thrombin-induced biphasic expression of cyclin D1, with first phase influencing cell migration and second phase directing cell proliferation.

Authors:  Venkatesh Kundumani-Sridharan; Dong Van Quyen; Jaganathan Subramani; Nikhlesh K Singh; Y Eugene Chin; Gadiparthi N Rao
Journal:  J Biol Chem       Date:  2012-05-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.